secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-09-08T11:05:42+00:00
Accession:  0001493152-26-041689
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Pharmaceuticals promotes Thomas Englese to Chief Commercial Officer
-------------------------------------------------------------------------

- Thomas Englese appointed Chief Commercial Officer, effective Sept 8, 2026, after serving as EVP Commercial Operations since 2024.
- Englese oversees commercial organization for TONMYA (fibromyalgia) and migraine products Zembrace SymTouch and Tosymra.
- Previous roles include CCO at Tris Pharma and Aziyo, and SVP/GM at Mallinckrodt.
- CEO Seth Lederman cites Englese's role in TONMYA launch; focus on expanding access and sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226041689/0001493152-26-041689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226041689/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-041689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer